Our observation that anti-TL1A reduced erosions independent of the joint clinical score is novel and reminiscent of results seen with anti-TNF agents in RA, where progression of erosions was inhibited independently of clinical improvement [1, 44]. This evidence concerns the gene TNFSF15 and rheumatoid arthritis.